Regulatory & Legal

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

Canada's space pioneer MDA is moving into land, sea, and air defence with a new subsidiary, aiming to capture billions in spending and boost national security.

With FAA and EASA approval for its new simulators, Boeing's delayed 777-9 program gains momentum, paving the way for airlines to prepare for the jet's debut.

Reaching over 90% of German mobile users, a new partnership aims to restore trust in the phone by displaying verified business names on incoming calls.

The mobile health firm now reaches 25 states with its tech-driven model, aiming to close care gaps and answer federal critics of in-home assessments.

Global banks are turning to mainframe modernization to boost resilience, meet new regulations, and power seamless digital experiences. Here's how.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

Supremex reports strong Q4 growth driven by its packaging division, erasing nearly all debt and positioning itself for an aggressive future beyond envelopes.

A new global study shows India leading in green energy commitment, while others lag. But the real challenge isn't just policy—it's a critical shortage of skills.

Following its transformative Porcupine acquisition, the miner posts huge profits and outlines a massive 2026 investment to double gold output.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

A landmark partnership will deliver 70M gallons of sustainable aviation fuel, fueled by corporate demand for decarbonization and key government incentives.

Early data on YOLT-202 shows it can safely restore normal protein levels in patients with Alpha-1 Antitrypsin Deficiency, a major step toward a cure.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

Discover how a unique state tax system allows individuals and corporations to fund K-12 scholarships for thousands at no additional cost.

Amundi secures regulatory approval for an ICG board seat, paving the way for a 9.9% stake and signaling a major strategic push into alternative assets.

A class action lawsuit reveals a massive pump-and-dump scheme targeting China Liberal Education, raising questions of corporate complicity and investor recourse.

As VerticalScope preps its 2025 results, investors watch if its pivot to AI and e-commerce can overcome ad market and search engine challenges.